Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.52 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.52 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | PANK3 | Q9H999 | 7/20 | 0.44 |
| ▸ | SMO | Q99835 | 3/20 | 0.43 |
| ▸ | PARP1 | P09874 | 4/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16627291 | 0.83 | HRH3 (0.61) | DPP4DPP8DPP9HRH3PANK3 | |
| SCHEMBL5093360 | 0.82 | DPP4 (0.52) | DPP4DPP8DPP9HRH3PANK3 | |
| SCHEMBL2825721 | 0.80 | HRH3 (0.55) | DPP4DPP8DPP9HRH3PANK3 | |
| SCHEMBL19748857 | 0.79 | HRH3 (0.54) | DPP4DPP8DPP9HRH3PANK3 | |
| SCHEMBL14349592 | 0.77 | EGLN2 (0.53) | DPP4DPP8DPP9HRH3PANK3 | |
| SCHEMBL231983 | 0.73 | KDM4E (0.51) | HRH3PANK3SMOGPR119 | |
| SCHEMBL30390836 | 0.73 | KDM4E (0.51) | HRH3PANK3SMOGPR119 | |
| SCHEMBL29514660 | 0.73 | KDM4E (0.54) | PANK3SMOGPR119 | |
| SCHEMBL14844043 | 0.73 | SMO (0.56) | PANK3SMOGPR119 | |
| SCHEMBL3048925 | 0.73 | KDM4E (0.54) | PANK3SMOGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465732-B2 | (2S,4S)-4-(piperazin-1-yl)pyrrolidine-2-methanone derivatives | PFIZER INC (US) | 2008-12-16 | — | — | US | disclosed |
| US-7291618-B2 | Therapeutic compounds | PFIZER INC (US) | 2007-11-06 | — | — | US | disclosed |
| US-20070161664-A1 | THERAPEUTIC COMPOUNDS | PFIZER INC | 2007-07-12 | — | — | US | disclosed |
| US-20070099897-A1 | Therapeutic compounds | PFIZER INC | 2007-05-03 | — | — | US | disclosed |
| US-20060079498-A1 | Therapeutic compounds | PFIZER INC | 2006-04-13 | — | — | US | disclosed |
| US-20050256310-A1 | Therapeutic compounds | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256310-A1 | Therapeutic compounds | REN, SLC5A1, SLC5A2 | DPP4 26/4885DPP8 413/4885DPP9 154/4885 |
| US-20070099897-A1 | Therapeutic compounds | SLC5A2, SLC5A1, REN | DPP4 31/4885DPP8 404/4885DPP9 182/4885 |
| US-20070161664-A1 | THERAPEUTIC COMPOUNDS | SLC5A2, SLC5A1, REN | DPP4 31/4885DPP8 404/4885DPP9 182/4885 |
| US-20060079498-A1 | Therapeutic compounds | SLC5A2, SLC5A1, REN | DPP4 31/4885DPP8 404/4885DPP9 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.